Skip to main content

A game changer for the treatment of osteoarthritis: a cost effective combined advanced therapy to treat knee osteoarthritis

Objective

According to the WHO Osteoarthritis (OA) is one major course of years lived with disability in the elderly and considered a high burden disease, which makes it a research priority in Europe. There is no cure for OA and SoA treatments need to be reconsidered. Current pharmacological interventions consist of analgesic, anti-inflammatory drugs as well as intraarticular steroids and hyaluronic acid (IA-HA) with moderate efficacy and associated long-term side effects. New medications are thus needed both to alleviate pain and slow down disease progression. Taking advantage of the explosion of RNA technologies in the last years, SINPAIN aims to develop a pipeline of siRNA-based therapy built on the combination of current technologies (dyanmic IA-HA and nanocarriers) that will be designed step-by-step in order to reach a successful management of inflammation and innervation therapy for the treatment of early (grade 0-1) and later stages (grade 3-4) of knee osteoarthritis (OA). To do so, a nanoformulation composed of functional IA-HA that can be loaded with vectors, for the delivery of siRNA targeting IL1? and NGF, and nanocarriers will be developed. In parallel, large effort will focus on understanding the pathological mechanisms of OA. To validate efficacy in relevant potency assays, 3D coculture models will be developed with human cells and tested in unique bioreactors mimicking joint environment and biomechanics. With the identified cell targets, IA-HA will be modified with immunomodulator peptide which will activate the adaptive immune response, responsible for OA regeneration. The 4 pipeline products of SINPAIN will be validated in vivo in a relevant OA model with SoA techniques that will demonstrate the reduced inflammation and pain, as well as the cartilage regeneration for the last product. Taking advantage of all the data obtained during the project, a decision-making tool based on machine learning will be validated to offer patients a personalized therapy.

Coordinator

FUNDACION CIDETEC
Net EU contribution
€ 1 286 250,00
Address
Paseo Miramon 196 Parque Tecnologico De Miramon
20014 San Sebastian
Spain

See on map

Region
Noreste País Vasco Gipuzkoa
Activity type
Research Organisations
Non-EU contribution
€ 0,00

Participants (9)

OZ BIOSCIENCES SAS
France
Net EU contribution
€ 509 605,00
Address
Parc Scientifique Et Technologique De Luminy Case 922 Bat Ccimp
13288 Marseille

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Provence-Alpes-Côte d’Azur Provence-Alpes-Côte d’Azur Bouches-du-Rhône
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
UNIVERSITAT DES SAARLANDES
Germany
Net EU contribution
€ 714 750,00
Address
Campus
66123 Saarbrucken

See on map

Region
Saarland Saarland Regionalverband Saarbrücken
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
ASPHALION SL
Spain
Net EU contribution
€ 204 375,00
Address
Calle Tarragona, Numeros 151-157, Planta 10, Bloqu
08014 Barcelona

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Este Cataluña Barcelona
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
I3S - INSTITUTO DE INVESTIGACAO E INOVACAO EM SAUDE DA UNIVERSIDADE DO PORTO
Portugal
Net EU contribution
€ 515 515,00
Address
Rua Alfredo Allen 208
4200-135 Porto

See on map

Region
Continente Norte Área Metropolitana do Porto
Activity type
Research Organisations
Non-EU contribution
€ 0,00
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO
Italy
Net EU contribution
€ 399 363,00
Address
Duomo 6
13100 Vercelli

See on map

Region
Nord-Ovest Piemonte Vercelli
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,75
EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GMBH
Germany
Net EU contribution
€ 460 125,00
Address
Heinrich-hertz-allee 1
66386 St Ingbert

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Saarland Saarland Saarpfalz-Kreis
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Non-EU contribution
€ 0,00
HASKOLINN I REYKJAVIK EHF
Iceland
Net EU contribution
€ 462 500,00
Address
Menntavegur 1
102 Reykjavik

See on map

Region
Ísland Ísland Höfuðborgarsvæði
Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
United States
Net EU contribution
€ 525 928,00
Address
Franklin Street 1111 12 Floor
94607 Oakland Ca

See on map

Activity type
Higher or Secondary Education Establishments
Non-EU contribution
€ 0,00
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
Net EU contribution
€ 309 146,00
Address
Rue De Tolbiac 101
75654 Paris

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Non-EU contribution
€ 0,25